Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.42 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059737 | 0.90 | MTNR1A (0.44) | NR1H4MTNR1AMTNR1BHTR2AHTR2C | |
| SCHEMBL8081516 | 0.86 | TP53 (0.47) | MTNR1AMTNR1B | |
| SCHEMBL3057632 | 0.81 | MTNR1A (0.44) | MTNR1AMTNR1BHTR2AHTR2C | |
| SCHEMBL3053596 | 0.80 | EP300 (0.42) | MTNR1AMTNR1BCNR1CNR2 | |
| SCHEMBL3054218 | 0.78 | HTT (0.49) | NR1H4MTNR1AMTNR1BCNR2 | |
| SCHEMBL9303578 | 0.78 | HTR2A (0.63) | MTNR1AMTNR1BHTR2AHTR2C | |
| SCHEMBL11254220 | 0.76 | CNR1 (0.47) | MTNR1AMTNR1BCNR1CNR2HTR2A | |
| SCHEMBL1395799 | 0.76 | HTR2A (0.52) | MTNR1AMTNR1BHTR2AHTR2C | |
| SCHEMBL2261530 | 0.75 | HTR2A (0.48) | MTNR1AMTNR1BHTR2AHTR2C | |
| SCHEMBL2020434 | 0.75 | MTNR1A (0.59) | MTNR1AMTNR1BHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2009026446-A9 | HDAC INHIBITORS | ARQULE, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009026446-A2 | HDAC INHIBITORS | ARQULE, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261710-A1 | HDAC Inhibitors | HDAC5, HDAC1, HDAC4 | NR1H4 758/4885FFAR1 2125/4885PTGDR2 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.